Clinical Trial

Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia

Completed Phase 2
View on ClinicalTrials.gov →
Summary
The main objectives of this study are to preliminarily evaluate the effectiveness of CG2001 in treating Chinese adult male AGA participants, determine the recommended dose for Phase III clinical studies, and evaluate the safety of CG2001 at the target dose.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-11; most recent amendment 2026-03-01.
Status change: Recruiting → Completed 2026-03-01
Trial Details
NCT Number NCT07076706
Lead Sponsor Beijing Dayspring Pharmaceutical Technology Co., Ltd
Conditions Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)
Enrollment 110 participants
Start Date 2024-12-05
Primary Completion 2025-08-26 (estimated)
Study Completion 2025-09-23 (estimated)
Updated on ClinicalTrials.gov 2026-03-03